A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine

NCT06608199 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines
Pneumococcal Infections

Interventions

BIOLOGICAL: pneumococcal disease prevention

Sponsor

Beijing Minhai Biotechnology Co., Ltd